SCAHB627 PECKC 3615

SENATE COMMITTEE AMENDMENTS
2018 Regular Session
Amendments proposed by Senate Committee on Health and Welfare to Reengrossed House
Bill No. 627 by Representative Lyons

1 AMENDMENT NO. 1

On page 1, line 2, after "reenact R.S. 40:1046(A)(2) and" delete the remainder of the line and
insert "(H)(2)(c) and to enact R.S. 40:1046(H)(2)(c) as amended and"

4 AMENDMENT NO. 2

On page 1, line 7, after "disorder;" and before "and to" insert "to provide for enactment of
 certain provisions upon reclassification of marijuana by the United States Drug Enforcement
 Administration; to provide for effectiveness;" and delete line 9 and insert:

"Section 1. R.S. 40:1046(A)(2) and (H)(2)(c) are hereby amended and reenacted to
 read as follows:"

10 AMENDMENT NO. 3

On page 2, line 24, after "physician" delete the remainder of the line and delete lines 25 and
26 and insert "complies with the provisions of this Section and consults with a pediatric
 subspecialist."

14 AMENDMENT NO. 4

On page 3, between lines 14 and 15, insert the following:

"H. * * *

(2) * * *

(c) The Louisiana State University Agricultural Center or the Southern
University Agricultural Center may conduct research on marijuana for therapeutic
use if the center is licensed as a production facility pursuant to this Section. Effective
January 1, 2020, and annually thereafter, the Louisiana State University Agricultural
Center and the Southern University Agricultural Center shall submit a report to the
Senate and House committees on health and welfare, to include data and outcomes
of the research conducted pursuant to this Paragraph.

* * *

26 AMENDMENT NO. 5

On page 3, line 17, after "reenacted" insert "and R.S. 40:1046(H)(2)(c) is hereby enacted"

28 AMENDMENT NO. 6

On page 3, after line 17, delete the remainder of the page and delete pages 4 and 5 in their
entirety and insert in lieu thereof the following:

"§1046. Prescription of marijuana for therapeutic use; rules and regulations;
Louisiana Board of Pharmacy and the adoption of rules and regulations
relating to the dispensing of prescribed marijuana for therapeutic use; the
Department of Agriculture and Forestry and the licensure of a production
facility

A. * * *

Page 1 of 3
This set of amendment(s) was prepared by Christine Arbo Peck.
(2)(a) For purposes of this Subsection, "debilitating medical condition" means any of the following:

(i) Cancer.
(ii) Positive status for human immunodeficiency virus.
(iii) Acquired immune deficiency syndrome.
(iv) Cachexia or wasting syndrome.
(v) Seizure disorders.
(vi) Epilepsy.
(vii) Spasticity.
(viii) Crohn's disease.
(ix) Muscular dystrophy.
(x) Multiple sclerosis.
(xi) Any of the following conditions associated with autism spectrum disorder:

(aa) Repetitive or self-stimulatory behavior of such severity that the physical health of the person with autism is jeopardized.
(bb) Avoidance of others or inability to communicate of such severity that the physical health of the person with autism is jeopardized.
(cc) Self-injuring behavior.
(dd) Physically aggressive or destructive behavior.

(b) No physician shall prescribe medical marijuana for treatment of any condition associated with autism spectrum disorder for a patient who is under the age of eighteen unless the physician complies with the provisions of this Section and consults with a pediatric subspecialist.

(c) If the United States Food and Drug Administration approves the use of medical marijuana in the same form provided for in this Part for any debilitating medical condition specifically identified in this Paragraph, that medical condition shall no longer be covered by the provisions of this Part.

(d) If the United States Food and Drug Administration approves the use of medical marijuana in a form or derivative different than provided for in this Part for any debilitating medical condition specifically identified in this Paragraph, the disease state shall remain covered by the provisions of this Part. The patient shall first be treated by the approved form or derivative of medical marijuana through utilization of step therapy or fail first protocols. If, after use of the United States Food and Drug Administration approved form or derivative of medical marijuana, the physician determines that the preferred treatment required under step therapy or fail first protocol has been ineffective in the treatment of the patient's debilitating medical condition, he may prescribe the form of medical marijuana provided for in this Part for use by the patient as medically necessary.

* * *

H.

* * *

(2) The Louisiana State University Agricultural Center or the Southern University Agricultural Center may conduct research on marijuana for therapeutic use if the center is licensed as a production facility pursuant to this Section. Effective January 1, 2020, and annually thereafter, the Louisiana State University Agricultural Center and the Southern University Agricultural Center shall submit a report to the Senate and House committees on health and welfare, to include data and outcomes of the research conducted pursuant to this Paragraph.

* * *

Section 3. This Section and Section 1 of this Act shall become effective upon signature by the governor or, if not signed by the governor, upon expiration of the time for bills to become law without signature by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If vetoed by the governor and subsequently approved by the legislature, this Section and Section 1 of this Act shall become effective on the day following such approval.
Section 4. This Section and Section 2 of this Act shall become effective and operative if and upon the date when the United States Drug Enforcement Administration reclassifies marijuana from a Schedule I drug to a Schedule II drug under the authority of the Controlled Substances Act, 21 U.S.C. 801 et seq."